mapping:
  Adamantinomatous craniopharyngioma: 23
  Adult-type diffuse high grade glioma, IDH-wildtype: 34
  Anaplastic neuroepithelial tumour with condensed nuclei: 76
  Angiocentric glioma, MYB/MYBL1-altered: 70
  Astroblastoma, MN1-altered, MN1:BEND2-fused: 44
  Astrocytoma, IDH-mutant: 3
  Atypical teratoid rhabdoid tumour: 11
  CIC-rearranged sarcoma: 61
  CNS Embryonal tumour with PLAG-family amplification: 90
  CNS Schwannoma, VGLL-fused: 91
  CNS embryonal tumour with BRD4:LEUTX fusion: 100
  CNS neuroblastoma, FOXR2-altered: 64
  CNS tumour with BCOR internal tandem duplication: 84
  CNS tumour with EP300:BCOR(L1) fusion: 98
  Cauda equina neuroendocrine tumour [paraganglioma], subtype non-CIMP: 80
  Central neurocytoma: 58
  Chordoid glioma, PRKCA-mutant: 66
  Chordoma: 21
  Control tissue, blood: 101
  Control tissue, reactive tumour microenvironment: 27
  Cribriform neuroepithelial tumour: 102
  Desmoplastic infantile ganglioglioma / desmoplastic infantile astrocytoma: 59
  Desmoplastic myxoid tumour, SMARCB1-altered: 103
  Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters: 68
  Diffuse glioneuronal tumour, subtype A: 105
  Diffuse hemispheric glioma, H3 G34-mutant: 39
  Diffuse leptomeningeal glioneuronal tumour: 75
  Diffuse midline glioma, H3 K27-altered: 15
  Diffuse paediatric-type high grade glioma: 8
  Dysembryoplastic neuroepithelial tumour: 20
  Ewing sarcoma: 26
  Extraventricular neurocytoma: 82
  Ganglioglioma: 28
  Germinoma: 53
  Haemangioblastoma: 38
  High-grade astrocytoma with piloid features: 50
  High-grade diffuse glioma of the midline/posterior fossa; H3/IDH-wildtype: 67
  Infant-type hemispheric glioma: 41
  Inflammatory microenvironment: 46
  Intraocular medulloepithelioma: 94
  Langerhans cell histiocytosis: 95
  Liponeurocytoma: 97
  Malignant melanotic nerve sheath tumour: 14
  Medulloblastoma, WNT activated: 42
  Medullomyoblastoma: 92
  Melanocytoma: 73
  Melanoma [metastatic]: 54
  Myxoid glioneuronal tumour, PDGFRA-mutant: 87
  Myxopapillary ependymoma: 13
  Neuroblastoma, MYCN subtype: 71
  Neuroblastoma, subtype ALT/TERT TMM positive: 85
  Neuroblastoma, subtype TMM negative: 32
  Neuroepithelial tumour with PATZ1 fusion: 65
  Neuroepithelial tumour, MN1:CXXC5-fused: 93
  Neuroepithelial tumour, PLAGL1-fused: 81
  Olfactory neuroblastoma: 40
  Oligodendroglioma, IDH-mutant and 1p/19q-codeleted: 9
  Oligosarcoma, IDH-mutant: 52
  Papillary craniopharyngioma: 19
  Papillary glioneuronal tumour: 88
  Pineal parenchymal tumour of intermediate differentiation: 56
  Pineal retinoblastoma: 78
  Pineoblastoma: 45
  Pineoblastoma, miRNA pathway altered, group 1: 35
  Pituicytoma, granular cell tumour of the sellar region, and spindle-cell oncocytoma: 33
  Pituitary adenoma: 6
  Plasmacytoma of the CNS: 63
  Pleomorphic xanthoastrocytoma: 16
  Plexiform neurofibroma: 36
  Polymorphous low-grade neuroepithelial tumour of the young: 96
  Posterior fossa subependymoma: 30
  Primary diffuse large B cell lymphoma of the CNS: 24
  Primary intracranial sarcoma, DICER1-mutant: 72
  Retinoblastoma: 107
  Retinoblastoma, MYCN-activated: 99
  Rhabdomyosarcoma: 29
  Rosette-forming glioneuronal tumour: 79
  Schwannoma: 55
  Sinonasal undifferentiated carcinoma, IDH2-mutant: 69
  Solitary fibrous tumour / haemangiopericytoma: 49
  Spinal ependymoma: 22
  Spinal ependymoma, MYCN-amplified: 77
  Subependymal giant cell astrocytoma: 48
  Supratentorial ependymoma, YAP1-fused: 86
  Supratentorial subependymoma: 57
  Teratoma: 51
  Yolk sac tumour: 74
  choroid plexus carcinoma: 62
  choroid plexus papilloma: 31
  control tissue: 17
  diffuse glioma, IDH-mutant and 1p19q retained [astroglial type]: 104
  diffuse glioma, MYB- or MYBL1-altered: 83
  embryonal tumour with multilayered rosettes: 25
  glioblastoma, IDH-wildtype: 0
  medulloblastoma Group 3: 18
  medulloblastoma Group 4: 12
  medulloblastoma, SHH-activated: 7
  meningioma, SMARCE1-altered: 89
  meningioma, benign: 4
  meningioma, intermediate: 10
  meningioma, malignant: 47
  normal pineal gland and pineocytoma: 106
  papillary tumour of the pineal region: 60
  pilocytic astrocytoma: 5
  posterior fossa ependymoma group A: 1
  posterior fossa ependymoma group B: 37
  spinal subependymoma: 43
  supratentorial ependymoma, ZFTA fusion-positive: 2
